Pain scale

Cancer Survivor, Caregiver Rethink Recovery, Launch RecoverEase Post-Surgical Garments for Drainage Bulb Comfort, Simplicity

Tuesday, October 19, 2021 - 2:23pm

In time for Breast Cancer Awareness Month, survivor Lauren May Woodruff and her recovery caregiver and friend Hannah Kenny have launched RecoverEase, a new line of garments that rethink and improve patients post-operative drain management.

Key Points: 
  • In time for Breast Cancer Awareness Month, survivor Lauren May Woodruff and her recovery caregiver and friend Hannah Kenny have launched RecoverEase, a new line of garments that rethink and improve patients post-operative drain management.
  • Her discomfort was amplified by the industry-standard recovery garment women must wear constantly for weeks following their procedure.
  • RecoverEase, a long-wearing, multi-functional garment that gives patients infinite options in drain placement, solves all of these problems.
  • RecoverEase is a wonderfully simple, pragmatic, patient-focused upgrade to the unwieldy aspect of drain management, states Ms. Woodruff.

Posture360 Receives Venture Capital to Drive Growth in Healthcare Industry

Thursday, October 14, 2021 - 2:00pm

"Incredibly, backpain is the most common symptom that people suffer from in their daily lives.

Key Points: 
  • "Incredibly, backpain is the most common symptom that people suffer from in their daily lives.
  • Our all-in-one digital health platform seamlessly integrates into our daily activities in non-evasive ways to boost overall health and wellness," says William Choi, Founder & CEO of Posture360.
  • Legendary Ventures isa US-based venture capital firm that fuels consumer, retail, and technology ("CRT") companies.
  • Legendary Ventures is a venture capital partnership that accelerates value creation for emerging companies operating across the CRT markets.

New Research Underscores Importance of World Spine Day

Tuesday, October 12, 2021 - 2:00pm

Reinforced with compelling new research like this, World Spine Day remains an important way of raising awareness about this global health issue.

Key Points: 
  • Reinforced with compelling new research like this, World Spine Day remains an important way of raising awareness about this global health issue.
  • World Spine Day was begun in 2008 by the World Federation of Chiropractic as an initiative to raise awareness around the prevention and effective management of spinal conditions.
  • In time for World Spine Day, the Canadian Chiropractic Association has launched its 'A Chiro Was Here' campaign.
  • "This World Spine Day let us all think about how we take care of our bodies and start healthy active habits," said Alison Dantas, CEO of the Canadian Chiropractic Association.

Niagara Falls To Be Illuminated On World Skin Health Awareness Day In Honor Of The Children's Skin Disease Foundation's Camp Wonder

Tuesday, October 12, 2021 - 2:00pm

Francesca Tenconi, founder of CSDF, was diagnosed at age eleven with pemphigusfoliaceous, a rare skin disease that left her constantly feeling different and isolated.

Key Points: 
  • Francesca Tenconi, founder of CSDF, was diagnosed at age eleven with pemphigusfoliaceous, a rare skin disease that left her constantly feeling different and isolated.
  • Her experiences drove her to create CSDF in 2000, and Camp Wonder launched a year later.
  • Wonder Wish, an initiative that grants wishes to Camp Wonder families, was created in 2017 to bridge the time between camp each summer.
  • Camp Wonder is a week-long, overnight summer camp for children and young adults residing in North America who have chronic and life-threatening skin disease.

Advisory - One lot of GENIUS Kids and Teens softgel capsules recalled due to possible bacterial contamination

Wednesday, October 6, 2021 - 8:30pm

Issue: Nutripur Inc. is recalling one lot (lot GC2210-1, expiry 08-23) due to possible bacterial contamination with Staphylococcus aureus, which may pose serious health risks.

Key Points: 
  • Issue: Nutripur Inc. is recalling one lot (lot GC2210-1, expiry 08-23) due to possible bacterial contamination with Staphylococcus aureus, which may pose serious health risks.
  • Children, teens and people with weakened immune systems may be more vulnerable to these risks.
  • What to do: Stop using the recalled product.
  • Nutripur Inc. is recalling one lot (lot GC2210-1, expiry 08-23)of GENIUS Kids and Teens softgel capsulesdue to possible bacterial contamination with Staphylococcus aureus, which may pose serious health risks.

Dr. Katinka van der Merwe of The Spero Clinic to Attend SuperConference 2021 Held by The Masters Circle Global

Wednesday, October 6, 2021 - 10:00am

FAYETTEVILLE, Ark., Oct. 6, 2021 /PRNewswire-PRWeb/ --We are proud to announce that Dr. Katinka van der Merwe will be a guest speaker at the 2021 Master Circle SuperConference.

Key Points: 
  • FAYETTEVILLE, Ark., Oct. 6, 2021 /PRNewswire-PRWeb/ --We are proud to announce that Dr. Katinka van der Merwe will be a guest speaker at the 2021 Master Circle SuperConference.
  • Dr. van der Merwe is known for effectively treating cases in which patients thought that attainable relief was not possible.
  • Dr. van der Merwe developed a unique Neurological Rehabilitation program, through which she has successfully treated thousands of hopeless cases.
  • Dr. Katinka van der Merwe grew up as the daughter of a successful chiropractor outside of Johannesburg, South Africa.

Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis

Tuesday, October 5, 2021 - 12:00pm

LEXINGTON, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced topline data from the non-IND/CTA clinical study evaluating KB295, a novel Microbiome Metabolic Therapy (MMT™), in mild-to-moderate ulcerative colitis (UC). The primary objective of safety and tolerability was achieved as KB295 was well tolerated and no safety concerns were observed. In the study, subjects receiving KB295 experienced a reduction in three biomarkers, fecal calprotectin (FCP), fecal lactoferrin, and FimH that are known to be associated with UC disease activity. These results are complemented by preclinical studies conducted with Kaleido’s unique translational ex vivo platform using human donor-derived microbiome communities.

Key Points: 
  • The primary objective of safety and tolerability was achieved as KB295 was well tolerated and no safety concerns were observed.
  • We are excited about the data package and look forward to advancing KB295 in a phase 2 ulcerative colitis study under an IND.
  • KB295 was evaluated in an exploratory, open-label, single arm non-IND clinical study in subjects with mild-to-moderate UC.
  • Subjects received KB295 for eight weeks, titrated up to 40g twice daily and then entered a two-week follow-up period.

High Watch Media Launches as First-Ever Production Company Dedicated to the Development of Feature-Length Content on Addiction and Mental Health

Monday, October 4, 2021 - 1:33pm

LAS VEGAS, Oct. 4, 2021 /PRNewswire/ -- Today, longtime film collaborators Jeff Reilly and Greg Williams will unveil High Watch Media a newly formed production company dedicated to developing and producing content inspired by recovery from addiction, mental health, and trauma.

Key Points: 
  • LAS VEGAS, Oct. 4, 2021 /PRNewswire/ -- Today, longtime film collaborators Jeff Reilly and Greg Williams will unveil High Watch Media a newly formed production company dedicated to developing and producing content inspired by recovery from addiction, mental health, and trauma.
  • "High Watch Media is our modern-day tribute to the life and spirit of one of the most influential people of the 20th century most people have never heard about."
  • High Watch Media is an independent production company organized to develop and produce feature-length stories with depth and weight.
  • Addiction and mental health are the most pressing challenge of our time, and High Watch Media is the first-of-its kind production company dedicated to the power of human stories of resilience and recovery without a profit motive.

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA® (ustekinumab) in Older Patients Across Approved Indications

Monday, October 4, 2021 - 1:00pm

After starting STELARA, call your doctor right away if you have any symptoms of an infection (see above).

Key Points: 
  • After starting STELARA, call your doctor right away if you have any symptoms of an infection (see above).
  • STELARA may decrease the activity of your immune system and increase your risk for certain types of cancer.
  • Some people who had risk factors for skin cancer developed certain types of skin cancers while receiving STELARA.
  • Tell your doctor right away if you develop shortness of breath or a cough that doesn't go away during treatment with STELARA.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Next Wave of Psychedelic Drug Development

Thursday, September 30, 2021 - 1:30pm

NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases.

Key Points: 
  • NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases.
  • While not being used for cancer, psychedelics are being evaluated to help patients better manage grief associated with cancer diagnoses.
  • Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is pursuing five indications in chronic pain and other indications with total estimated peak worldwide sales potential of more than $12 billion.
  • Tryp expects to initiate two Phase 2a studies in 2021 and two more in early 2022 focusing on these indications.